Figure S4

A. HNSCC

AXL inhibitor and UNC2025 Synergy	UM-SCC1 R428	UM-SCC4 R428	UM-SCC6 R428	UM-SCC47 R428	UM-SCC104 R428	UM-SCC1 siAXL
Expected	0.77+/-0.066	0.26+/-0.084	0.76+/-0.056	0.80+/-0.042	0.49+/-0.180	0.86+/-0.174
Observed	0.37+/-0.030	0.27+/-0.054	0.37+/-0.0175	0.39+/-0.043	0.32+/-0.121	0.61+/-0.098
Ratio (O : E)	0.49	1.04	0.48	0.49	0.65	0.71
Synergy	YES	---	YES	YES	---	---
p value (O vs E)	*	NS	*	*	NS	NS

TNBC

AXL inhibitor and UNC2025 Synergy	SUM229 R428	BT549 R428	MDAMB231 R428	MDAMB231 siAXL
Expected	0.61+/-0.042	0.54+/-0.085	0.55+/-0.091	0.68+/-0.047
Observed	0.45+/-0.050	0.33+/-0.019	0.37+/-0.063	0.53+/-0.053
Ratio (O : E)	0.73	0.62	0.67	0.79
Synergy	YES	---	YES	YES
p value (O vs E)	**	NS	*	**

NSCLC

AXL inhibitor and UNC2025 Synergy	H1299 R428	H1299 siAXL10	H1299 siAXL12	H157 siAXL10	H157 siAXL12
Expected	0.69+/-0.031	0.63+/-0.028	0.65+/-0.025	0.80+/-0.213	0.70+/-0.184
Observed	0.20+/-0.023	0.51+/-0.077	0.52+/-0.082	0.50+/-0.072	0.56+/-0.020
Ratio (O : E)	0.29	0.81	0.80	0.63	0.80
Synergy	YES	YES	YES	---	---
p value (O vs E)	***	**	***	NS	NS

B. UM-SCC1



MDAMB231



C. Esophageal



D. Esophageal



E. Esophageal

R428 and UNC2025 Synergy	KYSE270	OE33	OACM5.1C
Expected	0.78+/-0.050	0.70+/-0.023	0.43+/-0.032
Observed	0.39+/-0.005	0.40+/-0.009	0.24+/-0.012
Ratio (O : E)	0.49	0.57	0.57

Figure S4: AXL and MERTK inhibitors mediate synergistic inhibition of tumor cell expansion in vitro.
(A) HNSCC, TNBC, and NSCLC data were analyzed using the fractional product method to determine interactions between R428 and UNC2025 or siAXL and UNC2025. An observed effect of the combination treatment that was better than the expected effect for an additive interaction (O:E < 1) indicates synergy between agents. Mean values, standard errors, and statistical analyses were derived from 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001, NS=not significant. (B) Dose-effect relations of R428 and UNC2025 were used to generate isobolograms to assess synergism of combined treatment in UM-SCC1 and MDAMB231 cells. (C) Endogenous expression of TAM family kinases in esophageal cancer cell lines was determined by immunoblot. GAPDH was used as a loading control. (D) Esophageal cancer cell lines expressing both AXL and MERTK were treated with vehicle (DMSO), R428, UNC2025, or R428+UNC2025 for 72 hours and relative cell numbers were determined. Mean values and standard errors were derived from 2 independent experiments. (E) Interactions between R428 and UNC2025 in esophageal cancer cell lines were analyzed using the fractional product method.